MarketCap
Facebook
X
TelegramGeschäftsbericht 2020
hinzugefügt 19.08.2023
ASLAN Pharmaceuticals Limited Gesamtes Eigenkapital 2011-2026 | ASLN
Gesamtes Eigenkapital Jährlich ASLAN Pharmaceuticals Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | -10.2 M | -603 K | 30.6 M | 35.5 M | 41.6 M | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 41.6 M | -10.2 M | 19.4 M |
Gesamtes Eigenkapital Vierteljährlich ASLAN Pharmaceuticals Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 57.3 M | - | 75.4 M | - | -10.2 M | -11.6 M | -8 M | - | -603 K | 13.2 M | 18.4 M | - | 30.6 M | 41.8 M | - | - | 35.5 M | - | - | - | 41.6 M | - | - | - | -37.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 75.4 M | -37.6 M | 18.9 M |
Gesamtes Eigenkapital anderer Aktien in der Pharmaeinzelhändler
| Name | Gesamtes Eigenkapital | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
Graybug Vision
GRAY
|
-6.64 M | - | -11.23 % | $ 9.65 M |  USA |
 |
AbCellera Biologics
ABCL
|
967 M | $ 3.64 | -1.89 % | $ 1.09 B |  Canada |
 |
ADMA Biologics
ADMA
|
477 M | $ 16.45 | 0.43 % | $ 3.92 B | USA |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M |  China |
 |
ANI Pharmaceuticals
ANIP
|
404 M | $ 76.75 | 0.85 % | $ 1.48 B | USA |
 |
Apellis Pharmaceuticals
APLS
|
370 M | $ 19.93 | -1.14 % | $ 2.51 B | USA |
 |
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | USA |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M |  France |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |
 |
Aptorum Group Limited
APM
|
21.1 M | $ 0.83 | 4.23 % | $ 4.53 M | China |
 |
Athersys
ATHX
|
16.4 M | - | 3.77 % | $ 22.4 M | USA |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
45.9 M | - | - | $ 521 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-7.76 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
188 M | - | -4.8 % | $ 255 M | USA |
 |
Burford Capital Limited
BUR
|
1.7 B | $ 8.4 | -1.81 % | $ 1.39 B | Britain |
 |
Axsome Therapeutics
AXSM
|
88.3 M | $ 163.82 | -0.14 % | $ 8.15 B | USA |
 |
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | USA |
 |
BridgeBio Pharma
BBIO
|
-2.09 B | $ 66.98 | 3.8 % | $ 12.8 B | USA |
 |
CymaBay Therapeutics
CBAY
|
292 M | - | - | $ 3.45 B | USA |
 |
Avid Bioservices
CDMO
|
60.9 M | - | - | $ 789 M | USA |
 |
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-12.6 M | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
29.6 M | - | -16.75 % | $ 25.8 M | USA |
 |
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | USA |
 |
BioLineRx Ltd.
BLRX
|
22 M | $ 2.88 | 2.51 % | $ 908 M |  Israel |
 |
Clovis Oncology
CLVS
|
-279 M | - | -7.23 % | $ 13 M | USA |
 |
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | USA |
 |
BioMarin Pharmaceutical
BMRN
|
6.09 B | $ 60.75 | 3.79 % | $ 11.7 B | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
69.5 M | - | - | $ 231 M | USA |
 |
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | Canada |
 |
CTI BioPharma Corp.
CTIC
|
-17.6 M | - | - | $ 1.2 B | USA |
 |
CohBar
CWBR
|
15.3 M | - | -15.44 % | $ 2.2 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
-2.17 M | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-2.17 M | - | -4.36 % | $ 27 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
351 M | - | - | $ 2.18 B | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
Cabaletta Bio
CABA
|
236 M | $ 3.41 | 4.77 % | $ 3.98 M | USA |
 |
Capricor Therapeutics
CAPR
|
22.6 M | $ 25.71 | -0.5 % | $ 688 M | USA |
 |
AgeX Therapeutics
AGE
|
5.47 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
Codexis
CDXS
|
66.9 M | $ 1.1 | 12.24 % | $ 80.7 M | USA |
 |
Certara
CERT
|
1.06 B | $ 7.33 | 1.24 % | $ 1.18 B | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
31.2 M | - | - | $ 105 M | USA |
 |
Evofem Biosciences
EVFM
|
-66.5 M | - | 7.55 % | $ 38.1 M | USA |